[
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "1 and 3), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig. 4 and Tables 1 and 2).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "MSLCs engage their α4β1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [329] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Signaling regulation of SSCs and CSCs\nSignaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Signaling regulation of skin stem cell niche\nThe balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/β-catenin, YAP/TAZ, and Notch signaling pathways (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig. 3), with particular emphasis on melanoma, SCC, and BCC.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490].Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3β phosphorylation and β-catenin degradation [493, 494].Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The core signaling pathways, namely Shh, Wnt/β-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig. 3 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The potential signaling pathways targeted in both current and ongoing clinical trials (Fig. 4 and Table 1) are summarized below.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Shh signaling pathway\nTargeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Wnt/β-catenin signaling pathway\nSuppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suppressors of Wnt/β-catenin activation in skin cancers include β-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting YAP/TAZ signaling pathway\nSRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting Notch signaling pathway\nRO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "RO4929097, a small-molecule blocker of γ-secretase, shows potential benefits for skin cancer treatment (Fig. 4D), although its efficacy remains mixed.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway\nSeveral PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Several PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [117] (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [364] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig. 4E), particularly αvβ3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (α5β1 inhibitor, NCT00099970), and Intetumumab (anti-αv integrin antibody, NCT00246012).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  }
]